Cited by 324SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesRespiratory viral infections research

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Recent endemic coronavirus infection is associated with less severe COVID-19

Open access

Sagar, Manish, Reifler, Katherine, Rossi, Michael, Miller, Nancy S., Sinha, Pranay, White, Laura F., Mizgerd, Joseph P.·2021·Journal of Clinical Investigation

DOI 10.1172/jci143380PMC PMC7773342

Open this paper in CoChat — free account Open PDF

Abstract

Four different endemic coronaviruses (eCoVs) are etiologic agents for the seasonal common cold, and these eCoVs share extensive sequence homology with human SARS coronavirus 2 (SARS-CoV-2). Here, we show that individuals with, as compared with those without, a recent documented infection with eCoV were tested at greater frequency for respiratory infections but had a similar rate of SARS-CoV-2 acquisition. Importantly, the patients with a previously detected eCoV had less-severe coronavirus disease 2019 (COVID-19) illness. Our observations suggest that preexisting immune responses against endemic human coronaviruses can mitigate disease manifestations from SARS-CoV-2 infection.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci143380

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0994 · Cited by 8,249
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984
Prevalence of Asymptomatic SARS-CoV-2 Infection
Oran, D. P., & Topol, E. J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-3012 · Cited by 2,348
Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 states, march 1-30, 2020
Garg, S., Kim, L., Whitaker, M., O’Halloran, A., Cummings, C., Holstein, R., Prill, M., Chai, S. J., Kirley, P. D., Alden, N. B., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6915e3 · Cited by 2,335
Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults
Jain, S., Self, W. H., Wunderink, R. G., Fakhran, S., Balk, R., Bramley, A. M., Reed, C., Grijalva, C. G., Anderson, E. J., Courtney, D. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500245 · Cited by 2,323
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Le Bert, N., Tan, A. T., Kunasegaran, K., Tham, C. Y. L., Hafezi, M., Chia, A., Chng, M. H. Y., Lin, M., Tan, N., Linster, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2550-z · Cited by 1,887

Flagged first, then by citations

Show all 20 references

Research works printed but not linked: 1

10.1016/j.medj.2020.05 · DOI

Sorted by citations

Items 101–200 of 310

Does common cold coronavirus infection protect against severe SARS-CoV-2 disease?
Meyerholz, D. K., & Perlman, S. M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci144807 · Cited by 22
Broad respiratory testing to identify SARS-CoV-2 viral co-circulation and inform diagnostic stewardship in the COVID-19 pandemic
Marshall, N. C., Kariyawasam, R. M., Zelyas, N. J., Kanji, J. N., & Diggle, M. A. (2021) · Virology Journal · doi:10.1186/s12985-021-01545-9 · Cited by 22
Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naïve individuals
Jaago, M., Rähni, A., Pupina, N., Pihlak, A., Sadam, H., Tuvikene, J., Avarlaid, A., Planken, A., Planken, M., Haring, L., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-20849-6 · Cited by 23
T-Cell Immune Responses to SARS-CoV-2 Infection and Vaccination
Notarbartolo, S. (2024) · Vaccines · doi:10.3390/vaccines12101126 · Cited by 23
Absence of association between 2019‐20 influenza vaccination and COVID‐19: Results of the European I‐MOVE‐COVID‐19 primary care project, March‐August 2020
Kissling, E., Hooiveld, M., Brytting, M., Vilcu, A., de Lange, M., Martínez‐Baz, I., Sigerson, D., Enkirch, T., Belhillil, S., Meijer, A., et al. (2021) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12839 · Cited by 21
High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients
Greenbaum, U., Klein, K. L., Martínez, F. D., Song, J., Thall, P. F., Ramdial, J., Knape, C. G., Aung, F. M., Scroggins, J., Knopfelmacher, A. M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.675679 · Cited by 22
SARS-CoV-2-Specific T Cell Responses in Patients with COVID-19 and Unexposed Individuals
Rha, M., Kim, A. R., & Shin, E. (2021) · Immune Network · doi:10.4110/in.2021.21.e2 · Cited by 20
Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19 via Multi-Parameter Detection
Yuen, R. R., Steiner, D., Pihl, R. M. F., Chavez, E. C., Olson, A., Smith-Mahoney, E. L., Baird, L. A., Korkmaz, F. T., Urick, P., Sagar, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.614676 · Cited by 22
Self-citation
Do Islanders Have a More Reactive Behavioral Immune System? Social Cognitions and Preferred Interpersonal Distances During the COVID-19 Pandemic
Hromatko, I., Grus, A., & Kolđeraj, G. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.647586 · Cited by 21
Risk of severe COVID-19 infection among adults with prior exposure to children
Solomon, M. D., Escobar, G. J., Lu, Y., Schlessinger, D., Steinman, J. B., Steinman, L., Lee, C., & Liu, V. X. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204141119 · Cited by 22
Association of the past epidemic of Mycobacterium tuberculosis with mortality and incidence of COVID-19
Inoue, K., & Kashima, S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253169 · Cited by 20
Phytochemical Discrimination, Biological Activity and Molecular Docking of Water-Soluble Inhibitors from Saussurea costus Herb against Main Protease of SARS-CoV-2
Idriss, H., Siddig, B., González-Maldonado, P., El-Khair, H. M., Alakhras, A. I., Abdallah, E. M., Sotelo, P. H., & Elzupir, A. O. (2022) · Molecules · doi:10.3390/molecules27154908 · Cited by 20
Immune response induced by novel coronavirus infection
Sun, Y., Zou, Y., Wang, H., Cui, G., Yu, Z., & Ren, Z. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.988604 · Cited by 20
Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months
Serwanga, J., Ankunda, V., Sembera, J., Kato, L., Oluka, G. K., Baine, C., Odoch, G., Kayiwa, J. T., Auma, B. O., Jjuuko, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152522 · Cited by 20
SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severityPreprint
Laing, E. D., Epsi, N. J., Richard, S. A., Samuels, E. C., Wang, W., Vassell, R. A., Ewing, D. F., Herrup, R., Sterling, S. L., Lindholm, D. A., et al. (2021) · medRxiv · doi:10.1101/2021.04.27.21256207 · Cited by 20
Phenotypes and Functions of SARS-CoV-2-Reactive T Cells
Jung, M. K., & Shin, E. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0079 · Cited by 19
Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel
Ng, K. W., Faulkner, N., Wrobel, A. G., Gamblin, S. J., & Kassiotis, G. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101507 · Cited by 19
Heterotypic immunity from prior SARS-CoV-2 infection but not COVID-19 vaccination associates with lower endemic coronavirus incidence
Bean, D. J., Monroe, J., Liang, Y. M., Borberg, E., Senussi, Y., Swank, Z., Chalise, S., Walt, D. R., Weinberg, J., & Sagar, M. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ado7588 · Cited by 20
Self-citation
Adaptive immunity to human coronaviruses is widespread but low in magnitude
Tan, H., Lee, W. S., Wragg, K. M., Nelson, C., Esterbauer, R., Kelly, H. G., Amarasena, T. H., Jones, R. M., Starkey, G., Wang, B. Z., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1264 · Cited by 18
Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection
Lapp, S. A., Edara, V. V., Lu, A., Lai, L., Hussaini, L., Chahroudi, A., Anderson, L. J., Suthar, M. S., Anderson, E. J., & Rostad, C. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0256482 · Cited by 18
Epidemiology and Clinical Characteristics of Human Coronaviruses-Associated Infections in Children: A Multi-Center Study
Jo, K. J., Choi, S., Oh, C. E., Kim, H., Choi, B. S., Jo, D. S., & Park, S. E. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.877759 · Cited by 18
Knowledge into the Practice against COVID-19: A Cross-Sectional Study from Ghana
Yeboah, P. O., Daliri, D. B., Abdin, A. Y., Appiah-Brempong, E., Pitsch, W., Anto, B. P., Adusei, E. B. A., Razouk, A., Nasim, M. J., & Jacob, C. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182412902 · Cited by 18
Repeated Exposure to Subinfectious Doses of SARS-CoV-2 May Promote T Cell Immunity and Protection against Severe COVID-19
Angelis, M. L. D., Francescangeli, F., Rossi, R., Giuliani, A., Maria, R. D., & Zeuner, A. (2021) · Viruses · doi:10.3390/v13060961 · Cited by 17
Association of cellular immunity with severity of COVID-19 from the perspective of antigen-specific memory T cell responses and cross-reactivity
Fujii, S., Yamasaki, S., Iyoda, T., & Shimizu, K. (2022) · Inflammation and Regeneration · doi:10.1186/s41232-022-00239-1 · Cited by 18
T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components
Jing, L., Wu, X., Krist, M. P., Hsiang, T.-Y., Campbell, V. L., McClurkan, C. L., Favors, S. M., Hemingway, L. A., Godornes, C., Tong, D. Q., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.158126 · Cited by 18
Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysis
Ruiz, M. J., Siracusano, G., Cottignies-Calamarte, A., Tudor, D., Real, F., Zhu, A., Pastori, C., Capron, C., Rosenberg, A. R., Temperton, N. J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.842468 · Cited by 21
Age-Associated Seroprevalence of Coronavirus Antibodies: Population-Based Serosurveys in 2013 and 2020, British Columbia, Canada
Tanunliong, G., Liu, A. C., Kaweski, S. E., Irvine, M. A., Reyes, R. C., Purych, D., Krajden, M., Morshed, M. G., Sekirov, I., Gantt, S. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.836449 · Cited by 17
The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022
Sridhar, S., Chicz, R. M., Warren, W., Tartaglia, J., Savarino, S. J., Gurunathan, S., & Toussaint, J.-F. (2022) · Nature Communications · doi:10.1038/s41467-022-33549-6 · Cited by 16
Coronavirus Disease 2019 Mitigation Strategies Were Associated With Decreases in Other Respiratory Virus Infections
Sinha, P., Reifler, K. A., Rossi, M., & Sagar, M. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab105 · Cited by 16
Self-citation
Severe asthma in the era of COVID-19: A narrative review
Marques, J. G., van Zeller, M., Martins, P., & Loureiro, C. C. (2021) · Pulmonology · doi:10.1016/j.pulmoe.2021.04.001 · Cited by 20
Observations and Perspectives on Adaptive Immunity to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Dan, J. M., Antunes, R. D. S., Grifoni, A., Weiskopf, D., Crotty, S., & Sette, A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac310 · Cited by 16
T cells in SARS-CoV-2 infection and vaccination
Young, A. (2022) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355221115011 · Cited by 16
SARS-CoV-2 epitopes inform future vaccination strategies
Shafqat, A., Omer, M. H., Ahmad, O., Niaz, M., Abdulkader, H. S., Shafqat, S., Mushtaq, A. H., Shaik, A., Elshaer, A. N., Kashir, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1041185 · Cited by 15
Incidence and Severity of Covid-19 in Patients with and without Previously Verified Infections with Common Cold Coronaviruses
Ringlander, J., Martner, A., Nilsson, S., Westin, J., Lindh, M., & Hellstrand, K. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab089 · Cited by 16
Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4+ T-Cell Responses
Marklund, E., Leach, S., Nyström, K., Lundgren, A., Liljeqvist, J., Nilsson, S., Yilmaz, A., Andersson, L., Bemark, M., & Gisslén, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.750448 · Cited by 16
The Pandemic Experience in Southeast Asia: Interface Between SARS-CoV-2, Malaria, and Dengue
Yek, C., Nam, V. S., Leang, R., Parker, D. M., Heng, S., Kimsan, S., Sovannaroth, S., Mayxay, M., AbuBakar, S., Sasmono, R. T., et al. (2021) · Frontiers in Tropical Diseases · doi:10.3389/fitd.2021.788590 · Cited by 16
The Influence of Cross-Reactive T Cells in COVID-19
Eggenhuizen, P. J., & Ooi, J. D. (2024) · Biomedicines · doi:10.3390/biomedicines12030564 · Cited by 14
Viral Coinfection is Associated with Improved Outcomes in Emergency Department Patients with SARS-CoV-2
Goldberg, E. M., Hasegawa, K., Lawrence, A. C., Kline, J. A., & Camargo, C. A. (2021) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2021.8.53590 · Cited by 14
Antibody and T Cell Immune Responses to SARS-CoV-2 Peptides in COVID-19 Convalescent Patients
Garanina, E. E., Hamza, S., Stott-Marshall, R. J., Martynova, E. V., Markelova, M., Davidyuk, Y. N., Shakirova, V. G., Kaushal, N., Baranwal, M., Хаертынова, И. М., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.842232 · Cited by 13
BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children
Bartsch, Y. C., Chen, J. W., Kang, J., Burns, M. D., Denis, K. S., Sheehan, M. L., Davis, J. P., Edlow, A. G., Balazs, A. B., Yonker, L. M., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00575-w · Cited by 14
Proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell responses: A pilot study
Namuniina, A., Muyanja, E., Biribawa, V. M., Okech, B. A., Ssemaganda, A., Price, M. A., Hills, N. K., Nanteza, A., Bagaya, B. S., Weiskopf, D., et al. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001566 · Cited by 13
The immunopathogenesis of SARS-CoV-2 infection: Overview of lessons learned in the first 5 years
Yang, O. O. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf033 · Cited by 14
Favorable antibody responses to human coronaviruses in children and adolescents with autoimmune rheumatic diseases
Deakin, C. T., Cornish, G. H., Ng, K. W., Faulkner, N., Bolland, W., Hope, J., Rosa, A., Harvey, R., Hussain, S., Earl, C. P., et al. (2021) · Med · doi:10.1016/j.medj.2021.08.001 · Cited by 12
Differential pre-pandemic breast milk IgA reactivity against SARS-CoV-2 and circulating human coronaviruses in Ugandan and American mothers
Egwang, T. G., Owalla, T. J., Okurut, E., Apungia, G., Fox, A., Carlo, C. D., & Powell, R. L. R. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.039 · Cited by 12
A comprehensive review on efficient approaches for combating coronaviruses
Pouresmaieli, M., Ekrami, E., Akbari, A., Noorbakhsh, N., Moghadam, N. B., & Mamoudifard, M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112353 · Cited by 12
Peptide microarray IgM and IgG screening of pre-SARS-CoV-2 human serum samples from Zimbabwe for reactivity with peptides from all seven human coronaviruses: a cross-sectional study
Ashworth, J., Mathie, D., Scott, F., Mahendran, Y., Woolhouse, M. E. J., Stoevesandt, O., Mduluza, T., & Mutapi, F. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00295-6 · Cited by 12
T cell control of SARS-CoV-2: When, which, and where?
Diniz, M. O., Maini, M. K., & Swadling, L. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101828 · Cited by 12
Elucidating T Cell and B Cell Responses to SARS-CoV-2 in Humans: Gaining Insights into Protective Immunity and Immunopathology
Khanolkar, A. (2021) · Cells · doi:10.3390/cells11010067 · Cited by 12
Robust COVID-19 vaccination response after allogeneic stem cell transplantation using post transplantation cyclophosphamide conditioning
Morsink, L. M., van Doesum, J. A., Choi, G., Hazenberg, C. L. E., Biswana, A., Meppelink, F., Bungener, L. B., Lambeck, A. J. A., & Huls, G. A. (2022) · Blood Cancer Journal · doi:10.1038/s41408-021-00605-1 · Cited by 12
Epidemiology of Human Seasonal Coronaviruses Among People With Mild and Severe Acute Respiratory Illness in Blantyre, Malawi, 2011–2017
Kovacs, D., Mambule, I., Read, J. M., Kiran, A. M., Chilombe, M., Bvumbwe, T., Aston, S., Menyere, M., Masina, M., Kamzati, M., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad587 · Cited by 11
Highly conserved Betacoronavirus sequences are broadly recognized by human T cells
Neto, T. A. P., Zmasek, C. M., Avalos, L., Sidney, J., Trevizani, R., Phillips, E. J., Mallal, S. A., Frazier, A., Tan, G. S., Scheuermann, R. H., et al. (2025) · Cell · doi:10.1016/j.cell.2025.07.015 · Cited by 13
Cellular Immune Responses to SARS-CoV-2 in Exposed Seronegative Individuals
Norton, N. J., Holder, K. A., Ings, D. P., Harnum, D. O. A., Russell, R. S., & Grant, M. D. (2023) · Viruses · doi:10.3390/v15040996 · Cited by 11
Unravelling Antigenic Cross-Reactions toward the World of Coronaviruses: Extent of the Stability of Shared Epitopes and SARS-CoV-2 Anti-Spike Cross-Neutralizing Antibodies
Devaux, C. A., & Fantini, J. (2023) · Pathogens · doi:10.3390/pathogens12050713 · Cited by 11
The prospect of universal coronavirus immunity: characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses
Soni, M., Migliori, E., Fu, J., Assal, A., Chan, H. T., Pan, J., Khatiwada, P., Ciubotariu, R., May, M. S., Pereira, M. R., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1212203 · Cited by 12
Neglected roles of IgG Fc-binding protein secreted from airway mucin-producing cells in protecting against SARS-CoV-2 infection
Kobayashi, K., Tachibana, M., & Tsutsumi, Y. (2021) · Innate Immunity · doi:10.1177/17534259211043159 · Cited by 11
Low-dose and oral exposure to SARS-CoV-2 may help us understand and prevent severe COVID-19
Hausdorff, W. P., & Flores, J. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.11.171 · Cited by 10
Humoral response to SARS‐CoV‐2 and seasonal coronaviruses in COVID‐19 patients
Adams, O., Andrée, M., Rabl, D., Ostermann, P. N., Schaal, H., Lehnert, E., Ackerstaff, S., Müller, L., & Fischer, J. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27427 · Cited by 10
The therapeutic potential of regulatory T cells in reducing cardiovascular complications in patients with severe COVID-19
Saghafi, N., Rezaee, S. A., Momtazi‐Borojeni, A. A., Tavasolian, F., Sathyapalan, T., Abdollahi, E., & Sahebkar, A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120392 · Cited by 10
Frequent Infection of Cats With SARS-CoV-2 Irrespective of Pre-Existing Enzootic Coronavirus Immunity, Brazil 2020
de Oliveira-Filho, E. F., Carvalho, O., Carneiro, I. D. O., Fernandes, F. D., Vaz, S. N., Pedroso, C., González-Auza, L., Urbieta, V. C., Kühne, A., Mayoral, R., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.857322 · Cited by 10
Human seasonal coronavirus neutralization and COVID‐19 severity
Wells, D. A., Cantoni, D. M., Neto, M. M., Genova, C. D., Sampson, A., Ferrari, M., Carnell, G., Nadesalingam, A., Smith, P., Chan, A., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27937 · Cited by 12
T-cell immunity to SARS-CoV-2: what if the known best is not the optimal course for the long run? Adapting to evolving targets
Nowill, A. E., Caruso, M., & de Campos-Lima, P. O. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133225 · Cited by 10
Early protective effect of a (“pan”) coronavirus vaccine (PanCoVac) in Roborovski dwarf hamsters after single-low dose intranasal administration
Abdelaziz, M. O., Raftery, M. J., Weihs, J., Bielawski, O., Edel, R., Köppke, J. K. C., Vladimirova, D., Adler, J. M., Firsching, T. C., Voß, A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1166765 · Cited by 10
Antiviral Potential of Azelastine against Major Respiratory Viruses
Fischhuber, K., Bánki, Z., Kimpel, J., Kragl, N., Rössler, A., Bolze, A., Müllauer, B., Angerer, J., Nagy, G., Nagy, E., et al. (2023) · Viruses · doi:10.3390/v15122300 · Cited by 10
Distinct T cell polyfunctional profile in SARS-CoV-2 seronegative children associated with endemic human coronavirus cross-reactivity
Benede, N., Tincho, M. B., Walters, A., Subbiah, V., Ngomti, A., Baguma, R., Butters, C., Hähnle, L., Mennen, M., Skelem, S., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108728 · Cited by 10
Development of T cell antigen-based human coronavirus vaccines against nAb-escaping SARS-CoV-2 variants
Zhou, H., Leng, P., Wang, Y., Yang, K., Li, C., Ojcius, D. M., Wang, P., & Jiang, S. (2024) · 中国科学通报：英文版 · doi:10.1016/j.scib.2024.02.041 · Cited by 10
Lockdown Effects on Sars-CoV-2 Transmission – The evidence from Northern JutlandPreprint
Kepp, K. P., & Bjørnskov, C. (2021) · medRxiv · doi:10.1101/2020.12.28.20248936 · Cited by 12
Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection
Abela, I. A., Schwarzmüller, M., Ulytė, A., Radtke, T., Haile, S. R., Ammann, P., Raineri, A., Rueegg, S., Epp, S., Berger, C., et al. (2024) · mBio · doi:10.1128/mbio.02722-23 · Cited by 10
Pre-existing humoral immunity to low pathogenic human coronaviruses exhibits limited cross-reactive antibodies response against SARS-CoV-2 in children
Li, N., Li, X., Wu, J., Zhang, S., Zhu, L., Chen, Q., Fan, Y., Wu, Z., Xie, S., Chen, Q., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1042406 · Cited by 9
Current tobacco use and COVID-19 diagnoses in a cohort of adult clients of public dental clinics in Sweden
Galanti, M. R., Andersson, F., Caspersen, I. H., Peña, S., Karvonen, S., Magnus, P. M., Raffetti, E., Orsini, N., Magnusson, C., Shaaban, A. N., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-28091-4 · Cited by 9
Multicenter analysis of epidemiological and clinical features of pediatric acute lower respiratory tract infections associated with common human coronaviruses in China, 2014–2019
Han, S., Xu, B., Feng, Q., Feng, Z., Zhu, Y., Ai, J., Deng, L., Li, C., Cao, L., Sun, Y., et al. (2023) · Virology Journal · doi:10.1186/s12985-023-02198-6 · Cited by 9
Humoral and cellular immunity against diverse SARS-CoV-2 variants
Chen, C., Wang, X., & Zhang, Z. (2023) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2023.10.003 · Cited by 10
The immunobiology of SARS-CoV-2 infection and vaccine responses: potential influences of cross-reactive memory responses and aging on efficacy and off-target effects
Collins, C. P., Longo, D. L., & Murphy, W. J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1345499 · Cited by 9
The associations of previous influenza/upper respiratory infection with COVID-19 susceptibility/morbidity/mortality: a nationwide cohort study in South Korea
Kim, S. Y., Kim, J., Kim, M., Wee, J. H., Jung, Y., Min, C., Yoo, D. M., Sim, S., & Choi, H. G. (2021) · Scientific Reports · doi:10.1038/s41598-021-00428-x · Cited by 9
No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults
Ercanoglu, M. S., Gieselmann, L., Dähling, S., Poopalasingam, N., Detmer, S., Koch, M., Korenkov, M., Halwe, S., Klüver, M., Cristanziano, V. D., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103951 · Cited by 9
Coronavirus spike protein-specific antibodies indicate frequent infections and reinfections in infancy and among BNT162b2-vaccinated healthcare workers
Kolehmainen, P., Huttunen, M., Iakubovskaia, A., Maljanen, S., Tauriainen, S., Yatkin, E., Pasternack, A. H., Naves, R. A., Toivonen, L., Tähtinen, P. A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-35471-3 · Cited by 12
Most Japanese individuals are genetically predisposed to recognize an immunogenic protein fragment shared between COVID-19 and common cold coronaviruses
Dijkstra, J. M., Frenette, A. P., & Dixon, B. (2021) · F1000Research · doi:10.12688/f1000research.51479.1 · Cited by 10
Authors’ Reply to Sprengholz and Betsch: “Willingness to Pay for a COVID-19 Vaccine”
García, L. Y., & Cerda, A. A. (2021) · Applied Health Economics and Health Policy · doi:10.1007/s40258-021-00657-1 · Cited by 9
Co-immunization with spike and nucleocapsid based DNA vaccines for long-term protective immunity against SARS-CoV-2 Omicron
Pinto, P. B. A., Timis, J., Chuensirikulchai, K., Li, Q. H., Lu, H.-H., Maule, E., Nguyen, M. N., Alves, R. P. D. S., Verma, S. K., Ana‐Sosa‐Batiz, F., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-01043-3 · Cited by 8
Broad-spectrum coronavirus vaccines: integrated strategies to combat viral diversity
He, Q., Zhang, Y., Fu, Z., Ma, X., & Liang, Z. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2538561 · Cited by 8
Understanding COVID-19 Vaccines Today: Are T-cells Key Players?
Shafqat, A., Arabi, T. Z., Sabbah, B. N., Abdulkader, H. S., Shafqat, S., Razak, A., Kashir, J., AlKattan, K. M., & Yaqinuddin, A. (2022) · Vaccines · doi:10.3390/vaccines10060904 · Cited by 8
Unbiased immunome characterisation correlates with COVID-19 mRNA vaccine failure in immunocompromised adults
H-Vázquez, J., Cal‐Sabater, P., Arribas‐Rodríguez, E., Fiz‐López, A., Perez-Segurado, C., Martín‐Muñoz, Á., Prado, Á. D., Graciani, I. D. L. F., González, S. P., Gutiérrez, S., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1405217 · Cited by 8
Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines
Park, H., Park, M. S., Seok, J. H., You, J., Kim, J., Kim, J., & Park, M. (2022) · The Journal of Microbiology · doi:10.1007/s12275-022-1598-x · Cited by 8
Human T Cell Responses to Flavivirus Vaccines
Wullimann, D., & Ljunggren, H. (2025) · European Journal of Immunology · doi:10.1002/eji.70027 · Cited by 7
Detection of pre-existing SARS-CoV-2-reactive T cells in unexposed renal transplant patients
Anft, M., Blazquez‐Navarro, A., Stervbo, U., Skrzypczyk, S., Witzke, O., Wirth, R., Choi, M., Hugo, C., Reinke, P., Meister, T. L., et al. (2021) · Journal of Nephrology · doi:10.1007/s40620-021-01092-0 · Cited by 7
Effects of Antibody Responses to Pre-Existing Coronaviruses on Disease Severity and Complement Activation in COVID-19 Patients
Cugno, M., Meroni, P. L., Consonni, D., Griffini, S., Grovetti, E., Novembrino, C., Torri, A., Griffante, G., Gariglio, M., Varani, L., et al. (2022) · Microorganisms · doi:10.3390/microorganisms10061191 · Cited by 7
Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents
Ratcliffe, H., Tiley, K. S., Longet, S., Tonry, C. L., Roarty, C., Watson, C. J., Amirthalingam, G., Vichos, I., Morey, E., Douglas, N., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108500 · Cited by 8
SARS-CoV-2 humoral immunity in people living with HIV-1
Motsoeneng, B. M., Bhiman, J. N., Richardson, S. I., & Moore, P. L. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.05.005 · Cited by 7
Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization
Wang, J., Guo, C., Cai, L., Liao, C., Yi, H., Li, Q., Hu, H., Deng, Q., Lu, Y., Guo, Z., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.772511 · Cited by 7
A ubiquitous bone marrow reservoir of preexisting SARS-CoV-2-reactive memory CD4+ T lymphocytes in unexposed individuals
Li, J., Reinke, S., Yu, S., Schollmeyer, L., Liu, Y.-C., Wang, Z., Hardt, S., Hipfl, C., Hoffmann, U., Frischbutter, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1004656 · Cited by 7
An update on studies characterizing adaptive immune responses in SARS-CoV-2 infection and COVID-19 vaccination
Antunes, R. D. S., Grifoni, A., Frazier, A., Weiskopf, D., & Sette, A. (2023) · International Immunology · doi:10.1093/intimm/dxad014 · Cited by 8
Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia
Lynch, S. A., Subbarao, K., Mahanty, S., Barber, B. E., Roulis, E. V., van der Hoek, L., McCarthy, J. S., & Spann, K. M. (2021) · Viruses · doi:10.3390/v13081618 · Cited by 7
Boosted immunity to the common cold might protect children from COVID-19
Lavinder, J. J., & Ippolito, G. C. (2021) · Nature Immunology · doi:10.1038/s41590-021-01094-x · Cited by 7
Addressing Inequality in the COVID-19 Pandemic in Africa: A Snapshot from Clinical Symptoms to Vaccine Distribution
Pêgo, A. C., Lima, I. S., & Gozzelino, R. (2024) · COVID · doi:10.3390/covid4020014 · Cited by 6
Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2
Wei, X., Rong, N., & Liu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.993754 · Cited by 6
Act Early and at the Right Location: SARS-CoV-2 T Cell Kinetics and Tissue Localization
Bertoletti, A., Bert, N. L., & Tan, A. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810679 · Cited by 6
Intensivist coverage and critically ill COVID-19 patient outcomes: a population-based cohort study
Oh, T. K., Kim, S., & Song, I. (2023) · Journal of Intensive Care · doi:10.1186/s40560-023-00668-1 · Cited by 6
Do preexisting antibodies against seasonal coronaviruses have a protective role against SARS-CoV-2 infections and impact on COVID-19 severity?
Nasrallah, G. K. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103831 · Cited by 6
Altered pre-existing SARS-CoV-2-specific T cell responses in elderly individuals
Taira, N., Toguchi, S., Miyagi, M., Mori, T., Tomori, H., Oshiro, K., Tamai, O., Kina, M., Miyagi, M., Tamaki, K., et al. (2021) · Clinical Immunology Communications · doi:10.1016/j.clicom.2021.12.001 · Cited by 7
Multiplex Detection of Antibody Landscapes to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/Influenza/Common Human Coronaviruses Following Vaccination or Infection With SARS-CoV-2 and Influenza
Li, Z. N., Liu, F., Jefferson, S. N., Horner, L., Carney, P. J., Johnson, M. D. L., King, J. P., Martin, E. T., Zimmerman, R. K., Wernli, K. J., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac472 · Cited by 6
Pre‐existing immunity to SARS‐CoV‐2 associates with strong T cell responses induced by inactivated COVID‐19 vaccines
Yi, X., Wang, Y., Li, Q., Li, X., Zhang, P., Fu, X., Gu, S., Zhang, D., Liu, X., Lou, H., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28642 · Cited by 7

Authors: Sagar, M., Reifler, K., Rossi, M., Miller, N. S., Sinha, P., White, L. F., & Mizgerd, J. P.
Affiliations: Boston University (US)
Corresponding author: Sagar, Manish
Mizgerd, Joseph P.
ORCID: Sagar, Manish
Reifler, Katherine
Miller, Nancy S.
Sinha, Pranay
White, Laura F.
Mizgerd, Joseph P.
Venue: Journal of Clinical Investigation
Publisher: American Society for Clinical Investigation
Published: 2021-01-04
Volume: 131
Issue: 1
ISSN: 0021-9738 (ISSN-L)
1558-8238
DOI: 10.1172/jci143380
PMC: PMC7773342
OpenAlex: W3090049663
Cited by: 324
References: 20
Citations by year: 2026: 13 · 2025: 28 · 2024: 32 · 2023: 59 · 2022: 77 · 2021: 109
FWCI: 8.19
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Investigation (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (HL-135756, AI-145661, AI-052074, GM-122876)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
Keywords: endemic coronaviruses, SARS-CoV-2, COVID-19 severity, pre-existing immunity, cross-protection, common cold, immune response
MeSH terms: COVID-19, SARS-CoV-2, Adult, Aged, Antibodies, Viral, Female, Humans, Male, Middle Aged, Severity of Illness Index

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Recent endemic coronavirus infection is associated with less severe COVID-19

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks